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Summary The epidemiology of polycythaemia rubra vera (PV) has not been studied extensively in the past.
In 1968 PV became subject to cancer registration in England and Wales. The mortality rates and registration
rates for PV were abstracted for 1968-1982. The average annual mortality rates were 3.0/million/y (men, 1068
cases) and 2.3/million/y (women, 886 cases), there being no significant increase over the time period. The
average annual registration rates were 10.7/million/y (men, 3321 cases) and 6.7/million/y (women, 2207 cases)
and showed a large increase from 1968 to 1974 with a stable rate subsequently. This increase was
concentrated in the 65 + age groups. The median age of registration was 60-64 y with a peak ofmortality and
incidence between ages 75 and 84y. The data suggest some degree of overdiagnosis for PV registrations,
however the rates are comparable with those seen in other studies in developed countries. The routine data
sources require further validation, but they appear to provide useful information for the study of the
epidemiology of PV.
Polycythaemia rubra vera (PV) is a rare chronic
haematologic neoplasm that is characterised by a
clonal proliferation consisting primarily of erythro-
cytes with varying levels of granulocytes and
platelets (Adamson et al., 1976). Typically it has a
long clinical course that is often complicated by
thrombosis and may terminate in acute leukaemia
(Berk et al., 1981). There has been little
epidemiologic study of PV in recent years because
of its relative rarity and the lack of routine sources
of morbidity and mortality data. The introduction
of the 8th International Classification of Diseases
(ICD 8) in 1968 resulted in the transfer of PV into
the neoplastic subheading and so made PV subject
to cancer registration in England and Wales. The
purpose of this study is to describe the epi-
demiology of PV on a larger scale than has
previously been possible using the national cancer
registry and mortality data in England and Wales.
Materials and methods
Mortality data for PV (ICD 8 208 and ICD 9 238.4)
have been abstracted for the years 1968-1982
(Registrar General 1968-1973, OPCS 1974-1982).
Multicause coded mortality for 1973-1977 was
provided by OPCS from unpublished tabulations.
Cancer registrations for the same ICD codes were
taken from published data from 1968-1980
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(Registrar General Supplement on Cancer, 1972,
and OPCS Cancer Registrations 1971-1980). Rates
have been calculated using 5 year age bands, based
on the OPCS mid-year age and sex specific
population estimates. Standardised mortality
(SMR) and registration ratios (SRR) have been
calculated by indirect standardisation to the 1968
England and Wales male and female rates. Time
trends in standardised rates were tested for
significance using Spearman rank correlation
coefficients (Rs) (OPCS Morbidity Surveillance &
Siegel, 1956).
Results
The average annual mortality rate from 1968-1982
was 3.0/million/y for men (1068 cases) and
2.3/million/y for women (886 cases). There has been
no significant change in the SMR since 1968 for
either men (Rs=0.005, P>0.05) or women
(Rs=0.20, P>0.05) (Figure 1). The age specific
death rates peak between ages 75 and 84 (Figure
2a). The male death rate exceeds the female at
every age, except in the 85+ age group.
The average annual registration rate from 1968
to 1980 was 10.7/million/y for men (3321 cases) and
6.7/million/y for women (2207 cases). The SRR
increased to 160 in men (Rs=0.76, P<0.01) and
180 in women (Rs=0.66, P.<0.01) since 1968, but
there has been no significant change since 1974
(Figure 3). The increase in registrations has been
concentrated in the 65+ age groups (Figure 4). The
age specific registration rates show a pattern similar
© The Macmillan Press Ltd., 198660 A.V. PROCHAZKA & H.L.J. MARKOWE
cc
U)
Year
Figure 1 Polycythaemia rubra vera. Trends in Standardised Mortality Ratios 1968-1982, England and
Wales. (Base= 1968, England and Wales, male (0) and female (0) rates).
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Figure 2 Polycythaemia rubra vera. (a) Age specific mortality/million/y. England and Wales, 1968-1982 (0)
men, n= 1068; (0) women, n = 886. (b) Age specific registrations/million/y, England and Wales, 1968-1978,
(0) men, n =2712; (0) women, n = 1859.
C
0
In
-F
0
1
II
1EPIDEMIOLOGY OF POLYCYTHAEMIA VERA 61
200-
150-
cc 100
n
50-
a
1968 1970 1972
Figure 3 Polycythaemia
Standardised Registration
and Wales. (Base= 1968,
(0) and female (0) rates).
1974
Year
100
80
60
401
0 20
=U)
c 10
8
+ 6.
a) 4
2
1976 1978 1980
rubra vera. Trends in
Ratios 1968-1980, England
England and Wales, male
1968 1970 1972 1974 1976 1978 1980
Year
to that of the mortality rates (Figure 2b) with a
peak of incidence between ages 75 and 84. As with
mortality, the male rates exceed the female except
in the oldest age group. Both the registration and
mortality curves show the age specific rates in
women to be shifted by about 5-10 years to the
right of the males rates and to peak at a lower
level.
Discussion
There have been few studies of the epidemiology of
PV and little is known about the utility of routine
mortality and morbidity statistics as tools for the
study of PV. There are several problems which may
limit the usefulness of the routine data. Cancer
registrations are not generally subject to diagnostic
review. This is a particular problem with PV since
there are many common causes of secondary
erythrocytosis (Berlin, 1975). Dougan et al. (1981)
have shown that 30% of cases registered in Western
Australia as PV had a secondary cause of erythro-
cytosis after review of clinical records. There are no
comparable studies in England and Wales, but it is
likely that a similar degree of overdiagnosis exists.
Conversely, there may be cases who are not
diagnosed or not registered. There is wide variation
in the completeness of cancer registration in
England and Wales and it is estimated that some
regions register only 60% of cancer cases
(Balarajan & Scott, 1983). Since the survival in PV
is relatively good, a median of 10 years in clinical
series (Berk et al., 1981), one would expect some
excess of registrations over deaths. However, in PV
there is a 3-4 fold difference between the mortality
and registration rates. Some of this difference is due
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Figure 4 Polycythaemia rubra vera. (a) Men: Trends
in Age Specific Registration Rates, 1968-1980, England
and Wales. (b) Women: Trends in Age Specific
Registration Rates, 1968-1980, England and Wales.
Age groups: (0) 45-54y; (0) 55-64y; (A\) 65-74y;
(0) 75+ y.
to PV not being certified as the underlying cause of
death. Multicause coded death certificates for 1973-
1977 indicate that only 41% (640/1552) of deaths
with a mention of PV have PV coded as the
underlying cause of death. Many patients may be
dying of thrombosis or leukaemia which are not
attributed by the certifier to PV.
Chronic granulocytic leukaemia (CGL) is another
myeloproliferative disease that is related to PV. In
I
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clinical practice it is more common than PV, so
comparison of CGL rates with those of PV will
provide some estimate of the degree of accuracy
of PV registration. In England and Wales from
1968-1978, the death rate for CGL (ICD 8 205.1)
was 11.2/million/y for men (2933 cases) and
10.2/million/y for women (2839 cases). The regis-
tration rates were slightly lower: 10.3/million/y
for men (2701 cases) and 9.1/million/y for women
(2527) cases). The lower death rates for PV than
CGL fit with the clinical impression of relative
frequency. However, the registration rates are of
comparable magnitude. This suggests that over-
diagnosis may be a greater problem in the registra-
tion than the mortality data.
The broad agreement between the results of this
study and other epidemiologic studies of PV that
have used more rigorous methods of case ascertain-
ment suggest that the routine data sources may
provide meaningful information on the incidence of
PV (Table I). The range of rates varies from
0.2/million/y in Japan to 22/million/y in Minnesota,
which is a larger range than is seen in other
haematopoeitic neoplasms (Doll & Peto, 1981).
Waterhouse et al. (1982) have tabulated the
incidence of PV from a number of cancer registries.
The highest rates were 21/million/y in southeast
Scotland. The Japanese registries all had rates of
less than I/million/y, except for Nagasaki, where
the rates, based on only 18 male and 5 female
cases, were 16/million/y and 4/million/y respec-
tively. These differences in incidence could be
accounted for by differences in case ascertainment,
diagnostic practice or sampling error. However, the
generally low rate of PV in Japan, which also has
low rates of most other haematopoetic tumours
(Doll & Peto, 1981), suggests that there may be
environmental or genetic factors in Western
countries that are important in the aetiology of PV.
Since little is known about aetiologic factors in PV
other than a possible role of radiation (Caldwell et
al., 1984), further study of these international
differences and patterns of PV in migrants could
provide leads to the causation of PV.
There was a large increase in PV registration
rates, confined to the older age groups, from 1968
to 1974, without a corresponding increase in death
rates. There has not been any marked improvement
in therapy, which would lead to longer survival, so
this suggests that the increase in registration rates
in the early years was due to a learning curve of
registration of a 'new cancer' and better diagnosis
in the elderly, rather than to a true increase in
incidence. If this is the case then one would expect
that an increase in death rates would occur with a
lag of about 10 years, corresponding to the median
survival. Further tracking of PV rates over the next
5 years should confirm or refute this hypothesis.
The age and sex distribution of PV found in this
study is similar to that found in both epidemiologic
Table I Epidemiologic studies of the incidence ofpolycythaemia rubra vera
Time Number of
Author Method Location period cases Incidencea
Modan 1 Baltimore 1951-60 55 5.0
(1965)
Modan 1 Israel 1955-66 155 9.8
(1971)
Silverstein 1 Rochester 1935-69 19 22.2
(1971)
Kurita 2 Japan 1950-70 281 0.2
(1974)
Waterhouse 3 Birmingham 1935-70 100 5.1
(1974)
Dougan 3 Australia 1960-69 80 13.2
(1981)
Matilla 3 Finland 1968-76 177 5.4
(1981)
Present 3 England & 1968-80 5528 8.1
Study Wales
a(Cases/million/y) Directly standardised to European Standard Population.
Methods: (1) Hospital case notes, defined population base; (2) Survey of
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and clinical series of PV. Berk et al. (1981) found
that the median age at diagnosis was 62 years and
that 54% of cases were men, compared to a median
age of 60-64 and 60% men in the England and
Wales cancer registry data. In the epidemiologic
studies cited (Table I) and in Waterhouse et al.
(1982), the male incidence was uniformly greater
than the female rate. This male excess is small
compared with some other cancers and suggests
that the agent(s) of PV are not likely to be strongly
sex-linked factors. There does seem to be a
consistent shift of the female incidence and
mortality curves to the right of the male curves,
which may indicate either a delayed exposure or
decreased susceptibility in women to the causes
of PV.
The age curve of PV registrations shows a steep
rise and then a decline in the oldest age groups.
The slope (k) of the age curve of many cancers
from age 35 to 75 is linear on a log log scale and is
compatible with a multistage model of carcinogen-
sis in which k+ 1 cell changes are necessary for
development of an overt cancer (Doll, 1971). In a
review of the slopes of log age specific mortality
versus log age for various cancers, Cook et al.
(1969) found that there was relatively little
variation between countries in the slope for a
particular tumour. The slope of registrations for PV
to age 75 in England and Wales is 3.6 on a log log
scale and is similar for men and women.
Calculation of the slope from the studies in Table I
show that it ranges from 2.9 in Israel to 4.4 in
Finland. Assuming a simple multistage model, this
would suggest that at least four separate events
would be necessary for the development of PV. The
slope of the age curve for CGL in England and
Wales from 1968-78 was 2.5, which is shallower
than that seen in PV. This would suggest that PV
requires a longer induction time than does CGL
and more cellular changes to develop clinical
disease.
Another feature of the age curve is the decline in
incidence in the older age groups. This is probably
due to inadequate diagnosis and registration in the
elderly. A cohort effect of increasing early exposure
to an aetiologic agent would also give the same
pattern. A formal cohort analysis is not feasible on
the short time period for which registration data
are available, but the registration rates should show
a shift in the peak of incidence over time if a
cohort effect is present.
The consistency in the general pattern of
mortality and registration rates in England and
Wales, the similarity of the results to population
based studies using rigid diagnostic criteria, and the
congruence with clinical experience all suggest that
the routine statistics can provide a useful means of
studying PV. The main findings in this study are
that both mortality and registration rates are higher
in men than in women, the peak incidence occurs
between ages 75 and 84 and that the increase in
incidence since 1968 is probably due to improved
registration and diagnosis. There has been little
work on the epidemiology of PV in recent years
and this study has indicated that useful information
can be derived from routine statistical sources.
Replication of this approach in other countries and
validation of certification and registration of PV
would be of value to confirm the utility of the
routine data and to provide the basis for future
studies of the epidemiology and aetiology of PV.
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